Stock Financial Ratios, Dividends, Split History

AB / AllianceBernstein Holding L.P. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,880.49
Enterprise Value ($M)2,919.55
Book Value ($M)1,560.71
Book Value / Share15.98
Price / Book1.87
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Shares Outstanding 96,461,989
Common Shares Outstanding 96,461,989
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.13
Return on Assets (ROA)0.13
Return on Equity (ROE)0.13
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Net Income207.42
Cash Flow Statement (mra) ($M)
Cash From Operations202.41
Cash from Investing-20.11
Cash from Financing202.41
Identifiers and Descriptors
Central Index Key (CIK)825313
Related CUSIPS
01881G906 01881G956

Split History

Stock splits are used by AllianceBernstein Holding L.P. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Is AllianceBernstein Holding L.P. (AB) Stock Outpacing Its Finance Peers This Year?

2018-07-16 zacks
For those looking to find strong Finance stocks, it is prudent to search for companies in the group that are outperforming their peers. AllianceBernstein Holding L.P. (AB - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of AB and the rest of the Finance group's stocks. (9-0)

Has AllianceBernstein Holding L.P. (AB) Outpaced Other Finance Stocks This Year?

2018-07-13 zacks
The Finance group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AllianceBernstein Holding L.P. (AB - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. (4-0)

Cushion Your Portfolio with These 5 High Yielding Stocks

2018-06-22 zacks
After an exponential rise throughout 2017, the U.S. stock markets have been witnessing turmoil since February 2018. Factors like inflationary concerns, impending interest rate hike, global trade war fear, geopolitical conflicts in the Middle East, political turmoil in Europe, oil price fluctuations and many more, have heightened market fluctuations. Investment in high-dividend paying stocks, over a reasonable time period, is likely to bring good returns, especially when the market is plagued with severe volatility. (13-0)

Quants Might Not Be So Special Someday - Bloomberg

2018-06-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (11-0)

Legg Mason's (LM) CEO Pay Package for FY18 Jumps 8% Y/Y

2018-06-21 zacks
Legg Mason Inc.’s (LM - Free Report) chief executive officer (CEO) Joseph A. Sullivan’s total compensation, including a cash bonus, had been increased to $9.7 million in fiscal 2018. This represents a jump of 8% from the prior fiscal on higher incentives, according to a regulatory filing of Jun 20. In fiscal 2018, Sullivan’s pay package included salary of $500,000, unchanged from fiscal 2017, a cash bonus of $4 million (up from $3. (20-0)

CUSIP: 01881G106